Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

474 results about "Antitumor therapy" patented technology

Treatment with anti-VEGF antibodies

This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
Owner:GENENTECH INC

Antibodies against insulin-like growth factor 1 receptor and uses thereof

Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy.
Owner:F HOFFMANN LA ROCHE & CO AG

Methods and compositions for determining neoplastic disease responsiveness to antibody therapy

Methods are provided for determining whether a subject suffering from a neoplastic condition, e.g., non-Hodgkin's lymphoma (NHL), such as follicular lymphoma, is responsive to antineoplastic therapy, such as antibody therapy, e.g., Rituximab. In practicing the subject methods, an expression profile is obtained from the subject suffering from NHL and employed to determine whether the subject is responsive to antineoplastic therapy. In addition, reagents and kits thereof that find use in practicing the subject methods are provided.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Cobalamin conjugates for anti-tumor therapy

InactiveUS7232805B2BiocideSugar derivativesDiseaseTranscobalamin
The present invention provides a cobalamin-drug conjugate suitable for the treatment of tumor related diseases. Cobalamin is indirectly covalently bound to an anti-tumor drug via a cleavable linker and one or more optional spacers. Cobalamin is covalently bound to a first spacer or the cleavable linker via the 5′-OH of the cobalamin ribose ring. The drug is bound to a second spacer of the cleavable linker via an existing or added functional group on the drug. After administration, the conjugate forms a complex with transcobalamin (any of its isoforms). The complex then binds to a receptor on a cell membrane and is taken up into the cell. Once in the cell, an intracellular enzyme cleaves the conjugate thereby releasing the drug. Depending upon the structure of the conjugate, a particular class or type of intracellular enzyme affects the cleavage. Due to the high demand for cobalamin in growing cells, tumor cells typically take up a higher percentage of the conjugate than do normal non-growing cells. The conjugate of the invention advantageously provides a reduced systemic toxicity and enhanced efficacy as compared to a corresponding free drug.
Owner:INFLABLOC PHARMA

Use of nano structured lipid carrier drug feeding system

The invention discloses an application of nanometer structure lipid carrier administration system in the antineoplastic drug to reverse the multiple-drug tolerance of tumour cell, which comprises the following parts: solid lipid material, liquid lipid material and antineoplastic drug, wherein the rate of the liquid lipid (such as oleic acid) is 0-30wt%; the solid lipid is selected from monoglyceride; the liquid lipid is oleic acid; the antineoplastic drug is Paclitaxel or adriablastina. The invention has highly effective cell uptaking and cytolymph condensing function with packing molecular target in the antineoplastic drug of cell, which avoids P-glucoprotein in the drug tolerant cytolymph from identifying the antineoplastic drug to reduce exclusion.
Owner:ZHEJIANG UNIV

Cancer therapy using whole glucan particles and antibodies

InactiveUS20060165700A1Enhances tumoricidal activityHigh activityBiocideOrganic active ingredientsInnate immune systemCytotoxicity
The present invention relates to methods of using whole glucan particles and complement activating antibodies for antitumor therapy. Whole glucan particles enhance the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. This binding enhances innate immune system cytotoxicity, as well as stimulating the release of activating cytokines.
Owner:BIOPOLYMER ENG +2

Internal dry powder delivery system and method thereof

An internal dry powder delivery system through a working channel of an endoscopic cannula for directly applying the powder form medication to an internal tissue / organ site, includes an elongated tubular delivery channel and a powder supply device for producing pressurized gas mixing with the dry powder for feeding to form a mixture of dry powder and pressurized gas delivering to an internal tissue / organ site through the delivery channel via endoscopic cannula. It ensures a smooth powder release by preventing liquid from accumulation at the tip of the delivery channel and offers physicians a new powder form drug delivery method via endoscope. Also, it offers new minimal invasive application by directly and precisely applying the powder format drug to the internal sites of human gastrointestinal organ via endoscope to achieve hemostasis, anti-inflammation, anti-ulcer and anti-tumor treatment, etc.
Owner:ENDOCLOT PLUS INC

Polymer micelle lyophilized agent encapsulating insoluble antitumor drug

The invention belongs to the field of pharmaceutical agents, relates to a polymer micelle lyophilized agent encapsulating an insoluble antitumor drug as well as a preparation method and an application thereof. The polymer micelle lyophilized agent is prepared by carrying out molecular self-assembly on a methoxy poly(ethylene glycol) 2000-polyester block copolymer to form micelles, and then encapsulating the insoluble antitumor drug in a hydrophobic core formed by the polyester. The lyophilized agent has high encapsulation rate, high drug loading and small particle size, can significantly improve the water solubility of the insoluble drug and result in passive targeting of more antitumor drugs to concentrate in the tumor tissues, thus improving an anti-tumor treatment effect and reducing the toxic and side effects of drugs, and can be used to prepare the drugs used for the treatment of lung cancer, intestinal cancer, mammary cancer, ovarian cancer, etc. The lyophilized agent can also be quickly dissolved and dispersed to form a transparent micellar solution after water for injection, normal saline solution and the like are added, and is used for the preparation of the drugs for treating primary intestinal cell carcinoma.
Owner:上海谊众药业股份有限公司

Preparation method and application of autologous CAR (chimeric antigen receptor)-T cell

The invention relates to a preparation method and application of an autologous CAR (chimeric antigen receptor)-T cell. An established CD28-CD137-CD19-CD3 full-length gene is guided into a T-cell of a patient by a CRISPR / Cas9 technology to prepare the CAR-T cell, and the CAR-T cell is subjected to expansion in vitro and then returns in the body of the patient to perform anti-tumor treatment. Compared with the traditional tumor treatment method, the method has the advantages that the method is cell targeted therapy and small in side effect; the gene modified T cell can stably express an antigen binding domain on the surface and identify a target antigen, and does not have MHC limit; and the tumor treatment effect is improved.
Owner:GUANGDONG PANGUARD CELL BIOLOGICAL TECH CO LTD

Peptide antiestrogen compositions and methods for treating breast cancer

InactiveUS6306832B1Low backgroundReduction of nonspecific backgroundPeptide/protein ingredientsGenetic material ingredientsCo activatorCancer research
Disclosed are methods and compositions comprising native, site-specifically mutagenized, and synthetic peptides comprising portions of the human estrogen receptor, or estrogen receptor co-activator, and nucleic acid compositions encoding these polypeptide compositions. Also disclosed are methods for synthesizing phosphotyrosyl and malonyltyrosyl peptide derivatives and their use as antiestrogen compositions in the treatment of breast cancers, the preparation of pharmaceutical compositions, diagnostic kits, and the development of related assays for use in antitumor therapies.
Owner:UNIVERSTIY OF CALIFORNIA

Antitumoral combinations containing et-743 and a cruciferous and a cruciferous indole compound

Administration of a cruciferous indole compound can reduce undesirable toxic side effects inherent in the anti-tumor therapy with ET-743 before during or after administration of the ET-743.
Owner:PHARMA MAR U

Preparation and application of dual-sensitivity amphiphilic polysaccharide-doxorubicin conjugate and pharmaceutical composition thereof

The invention relates to a dual-sensitivity amphiphilic polysaccharide-doxorubicin conjugate.According to the conjugate, hydrophobic antitumor drug doxorubicin is introduced in a polysaccharide framework through a connecting arm containing a disulfide bond and a hydrazone bond, so that the polysaccharide-doxorubicin conjugate has an amphiphilic property, can be self-assembled into a nano-micelle in water and directly used for tumor treatment, and can also be physically loaded with an antitumor drug to be used for antitumor treatment.The conjugate is mainly characterized in that after the nano-micelle reaches a focus, the disulfide bond in the connecting arm can be degraded specifically by high-concentration reduction substances in focus cells, and meanwhile the hydrazone bond in the connecting arm can be degraded in a special pH environment of the focus, so that the micelle is degraded, the drug is quickly released, and the treatment effect is improved; the antitumor drug is loaded in two modes of chemical conjugation and physical package, and therefore the joint treatment effect is achieved.The polysaccharide conjugate and a pharmaceutical composition can be used for injection or oral administration or external administration, can remarkably improve antitumor activity, and provides a new thought for development of the antitumor drug.
Owner:CHINA PHARM UNIV

Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy

The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.
Owner:VEGENICS PTY LTD

CD19-based chimeric antigen receptor and application thereof

The invention relates to a CD19-based chimeric antigen receptor and application thereof, in particular to a lentivirus vector material built by a chimeric antigen receptor T (CAR-T) cell technology using a tumor specific target point CD19 as the basis, a method, and application thereof to anti-tumor treatment. The chimeric antigen receptor is formed by serially connecting an antigen combination structure domain, a membrane spaning structure domain, a costimulatory signal conduction region, a CD3 zeta signal conduction structure domain and an inducible suicide fusion structure domain, wherein the antigen combination structure domain is combined with the tumor surface antigen; the tumor surface antigen is CD19. The chimeric antigen receptor is subjected to specific gene transformation on theT cell stimulation signals. Compared with other chimeric antigen receptors, the chimeric antigen receptor provided by the invention has a better reaction effect and higher safety, so that the CAR-T cells have higher immune effects and low side effects; the treatment effect and safety of the CAR-T cells are enhanced.
Owner:BEIJING MEIKANG JIMIAN BIOTECH CO LTD

Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells

The invention relates to a genetically modified mesenchymal stem cell (MSC) and medical use thereof in the treatment of tumours, said MSC comprising one or more exogenous nucleic acid molecule(s), wherein said exogenous nucleic acid molecule(s) comprise a region encoding one or more immune response-stimulating or immune response-modulating cytokine(s) operably linked to a promoter or promoter / enhancer combination. The invention encompasses the use of said cells in modulating the tumour microenvironment in order to attract immune effector cells and facilitate their activation and / or adoption of a memory phenotype. One aspect of the invention relates to the use of said cells in anti-tumour treatment comprising the combined administration of said mesenchymal stem cells with anti-tumour immunotherapies, such as checkpoint inhibitors, immune cells, for example T cells, such as T cells with artificial T cell receptors, for example a chimeric antigen receptor (CAR-Ts) or exogenous T-Cell Receptor (TCR) transduced cells, NK cells or macrophages / monocytes, or a cancer vaccine.
Owner:APCETH GMBH & CO KG

Embedded antigen receptor based on CD30 and application thereof

The invention relates to an embedded antigen receptor based on CD30 and application thereof, and particularly relates to a building method of an embedded antigen receptor T (CAR-T) cell technology based on a tumor specific target site CD30 and application thereof in anti-tumor treatment. The embedded antigen receptor is prepared by connecting an antigen binding structural domain, a transmembrane structural domain, a costimulatory signal conducting region and a CD3 zeta signal conducting structural domain in series, wherein the antigen binding structural domain is combined with tumor-surface antigen, and the tumor-surface antigen is CD30. By adopting the embedded antigen receptor, specific gene transformation on a single chain antibody of the tumor-surface antigen CD30 is carried out, and because of the transformed antibody, the binding force of the antigen-antibody is stronger, and the mutation difficultly occurs; compared with other embedded antigen receptors and other tumor antigens, the embedded antigen receptor has a better effect, and the expression quantity of the target site is high, so that an immunization effect of CAR-T cells is enhanced, and a treatment effect on the CAR-T cells is enhanced.
Owner:SHENZHEN GENO IMMUNE MEDICAL INST

Targeting of ews-fli1 as Anti-tumor therapy

Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein.
Owner:GEORGETOWN UNIV

Internal dry powder delivery system and method thereof

An internal dry powder delivery system through a working channel of an endoscopic cannula for directly applying the powder form medication to an internal tissue / organ site, includes an elongated tubular delivery channel and a powder supply device for producing pressurized gas mixing with the dry powder for feeding to form a mixture of dry powder and pressurized gas delivering to an internal tissue / organ site through the delivery channel via endoscopic cannula. It ensures a smooth powder release by preventing liquid from accumulation at the tip of the delivery channel and offers physicians a new powder form drug delivery method via endoscope. Also, it offers new minimal invasive application by directly and precisely applying the powder format drug to the internal sites of human gastrointestinal organ via endoscope to achieve hemostasis, anti-inflammation, anti-ulcer and anti-tumor treatment, etc.
Owner:ENDOCLOT PLUS INC

Ternary complex nanometer system and preparation method and application thereof

The invention discloses a ternary complex nanometer system and a preparation method and application thereof. The system comprises an iron compound, a benzene-ring-containing micromolecule antineoplastic active compound and a polyphenol compound; a weight ratio of the iron compound to the benzene-ring-containing micromolecule antineoplastic active compound to the polyphenol compound is (1 to 4):(2to 10):(5 to 20). Relative to the prior art, according to the invention, different micromolecule compounds or medicines can be stably assembled only by a physical assembling means; the formed complexnanometer medicine not only has an antineoplastic treatment effect of the micromolecule antineoplastic active compound, but also has a ferroptosis treatment effect that the iron compound reacts with the polyphenol compound are mediated on the basis of an intracellular Fenton reaction; moreover, the novel complex nanometer medicine formed by the preparation method disclosed by the invention furtherhas an outstanding photothermal effect; chemotherapy, ferroptosis treatment and photothermal therapy can be integrated into one whole body, take a synergistic effect, beneficiate each other and achieve an all-in-one combined antineoplastic treatment effect.
Owner:CHINA PHARM UNIV

Embedded antigen receptor based on CD22 and application thereof

The invention relates to an embedded antigen receptor based on CD22 and application thereof, and particularly relates to a building method of an embedded antigen receptor T (CAR-T) cell technology based on a tumor specific target site CD22 and application thereof in anti-tumor treatment. The embedded antigen receptor is prepared by connecting an antigen binding structural domain, a transmembrane structural domain, a costimulatory signal conducting region and a CD3 zeta signal conducting structural domain in series, wherein the antigen binding structural domain is combined with tumor-surface antigen, and the tumor-surface antigen is CD22. By adopting the embedded antigen receptor, specific gene transformation on a single chain antibody of the tumor-surface antigen CD22 is carried out, and because of the transformed antibody, the binding force of the antigen-antibody is stronger, and the mutation difficultly occurs; compared with other embedded antigen receptors and other tumor antigens, the embedded antigen receptor has a better effect, and the expression quantity of the target site is high, so that an immunization effect of CAR-T cells is enhanced, and a treatment effect on the CAR-T cells is enhanced.
Owner:SHENZHEN GENO IMMUNE MEDICAL INST

Uses of chlorogenic acid in preparation of drugs treating multidrug resistance of cancer

InactiveCN104758277AContinuous effective treatmentSolve the limit problem that cannot continue effective treatmentOrganic active ingredientsAntineoplastic agentsChlorogenic acidMultidrug Resistance Induction
The invention discloses new medicinal uses of chlorogenic acid, especially uses of chlorogenic acid in preparation of drugs treating multidrug resistance of cancer, and provides uses of chlorogenic acid and antitumor drugs in preparation of drugs treating cancer. By inhibiting activity and expression of drug pump protein on surfaces of tumor cells, tumor patients generating multidrug resistance can receive durable and effective treatment. A combination of the chlorogenic acid and a drug-resistant drug is provided, thus alleviating or eliminating drug resistance to multiple drugs for patients, allowing patients with drug resistance to receive durable and effective treatment, and overcoming the limitation problem at present that tumor patients cannot receive durable and effective treatment due to generation of drug resistance. The uses have important meaning in clinical use of antitumor treatment.
Owner:刘晓梅

Modulation of nitric oxide signaling to normalize tumor vasculature

The instant invention provides methods for treating a solid tumor in a subject comprising modulating nitric oxide production in the tumor to normalize tumor vasculature and administering an anti-tumor therapy to the subject. The invention further provides methods of treating a solid tumor in a subject comprising selectively increasing cyclic guanosine monophosphate (cGMP) or cGMP dependent protein kinase G production in the tumor vasculature to an amount effective to normalize tumor vasculature and administering an anti-tumor therapy to the subject.
Owner:THE GENERAL HOSPITAL CORP

Novel methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation

The present invention relates to methods for prognosis, diagnosis, and treatment of malignant tumors that were treatment resistant. The present invention provides methods of prognosis and diagnosis of multidrug resistant tumors through detection of the expression levels of nuclear co-repressor 2 (“N-CoR2”), histone deacetylases 3 (“HDAC3”), and their associated gene expression biomarkers. The present invention also provides methods of sensitizing tumors to anti-tumor therapeutics by disrupting HDAC3 activation, abrogating the N-CoR2-HDAC3 interaction, inhibiting the activity of either protein, or by down-regulating the expression of either protein.
Owner:RGT UNIV OF CALIFORNIA

Targeting of ews-fli1 as Anti-tumor therapy

Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein.
Owner:GEORGETOWN UNIV

Defective recombinant adenoviruses expressing cytokines for antitumor treatment

A recombinant nucleic acid used for the production of a defective adenovirus containing an inserted sequence coding for a cytokine under the control of a promoter in the genomic sequence of the recombinant adenovirus. This recombinant adenovirus is useful in the preparation of anti-tumoral drugs which can be directly injected into the tumor of the host.
Owner:CENT NAT DE LA RECHERCHE SCI +1

Chimeric antigen receptor based on CD20, and applications thereof

The invention relates to a chimeric antigen receptor based on CD20, and applications thereof, and more specifically relates to a cell technology construction method of chimeric antigen receptor T (CAR-T) taking tumor specific target spot CD20 as a base, and applications of the chimeric antigen receptor T in treatment of tumor. The chimeric antigen receptor T is composed of an antigen binding domain, a transmembrane domain, a costimulatory signal transduction region, and a CD3 zeta signal transduction domine via series connection; wherein the antigen binding domain is used for binding tumor surface antigens, and the tumor surface antigen is CD20. According to applications, specific gene modification of single-chain antibody of tumor surface antigen CD20 is carried out, the modified antibody is capable of increasing antigen-antibody binding force, mutation is not easily caused. Compared with other chimeric antigen receptors and other tumor antigens, the chimeric antigen receptor possesses following advantages: the effect is better, target spot expression quantity is higher, immune effect on CAR-T cells is improved, and treatment effect of CAR-T cells is improved.
Owner:SHENZHEN GENO IMMUNE MEDICAL INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products